Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

grunenthal italia s.r.l. - lornoxicam - lornoxicam

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

laboratoires bailleul s.a. - minoxidil - minoxidil

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - levonorgestrelum - tablet - levonorgestrelum 1.5 mg, cellulosum microcristallinum, lactosum monohydricum 43.3 mg, poloxamerum 188, carmellosum natricum conexum corresp. natrium 0.45 mg, magnesii stearas, pro compresso. - ormonale contraccettivo di controllo delle nascite in caso di emergenza - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - levonorgestrelum, ethinylestradiolum - confetti - levonorgestrelum 150 µg, ethinylestradiolum 30 µg, lactosum monohydricum 52.353 mg, maydis per amylum, povidonum k 25, talco, magnesio stearas, Überzug: povidonum k 90, talco, glycerolum, sintetico 14.187 mg, calcio carbonas, macrogolum 6000, e-171, cera carnauba per compresso haze. - contraccezione ormonale - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

laboratorios farmaceuticos rovi s.a. - enoxaparina sodica - enoxaparina sodica

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

famy care europe ltd - levonorgestrel ed estrogeno - levonorgestrel ed estrogeno

Unione Europea - italiano - EMA (European Medicines Agency)

baxalta innovations gmbh - vonicog alfa - malattie di von willebrand - antiemorragici - veyvondi è indicato negli adulti (età 18 anni) con malattia di von willebrand (vwd), quando la desmopressina (ddavp) al solo trattamento è inefficace o non è indicato per il trattamento di emorragie e sanguinamento chirurgico per la prevenzione del sanguinamento chirurgico. veyvondi non deve essere usato nel trattamento dell'emofilia a.

Unione Europea - italiano - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazolo - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimicotici per uso sistemico - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 e 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 e 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 e 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 e 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 e 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 e 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 e 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- aspergillosi invasiva in pazienti con malattia refrattaria ad amfotericina b o ad itraconazolo o in pazienti intolleranti a questi farmaci;- fusariosi in pazienti con malattia refrattaria ad amfotericina b o in pazienti che sono intolleranti di amfotericina b;- chromoblastomycosis e mycetoma in pazienti con malattia refrattaria ad itraconazolo o in pazienti che sono intolleranti di itraconazolo;- coccidioidomicosi in pazienti con malattia refrattaria ad amfotericina b, itraconazolo o fluconazolo o in pazienti intolleranti a questi farmaci;- candidiasi orofaringea: come terapia di prima linea in pazienti che hanno grave malattia o immunocompromessi, in cui la risposta alla terapia attuale è previsto per essere poveri. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Unione Europea - italiano - EMA (European Medicines Agency)

csl behring gmbh - fattore viii della coagulazione umano, umano, fattore di von willebrand - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - la malattia di von willebrand (vwd)la profilassi e il trattamento di emorragia o sanguinamento chirurgico in pazienti con vwd, quando desmopressina (ddavp) al solo trattamento è inefficace o controindicato. emofilia a (congenita di fattore viii carenza)la profilassi e il trattamento delle emorragie in pazienti con emofilia a.

Unione Europea - italiano - EMA (European Medicines Agency)

biogen netherlands b.v.  - interferone beta-1a - sclerosi multipla - immunostimolanti, - avonex è indicato per il trattamento di:pazienti con diagnosi recidivanti di sclerosi multipla (ms). negli studi clinici, questo è stato caratterizzato da due o più esacerbazioni acute (ricadute) nei tre anni precedenti, senza evidenza di progressione continua tra le recidive; avonex rallenta la progressione della disabilità e diminuisce la frequenza delle recidive;i pazienti con un singolo evento demielinizzante con un processo infiammatorio attivo, se è abbastanza grave da giustificare il trattamento con corticosteroidi per via endovenosa, se la diagnosi alternative sono stati esclusi, e se essi sono considerati ad alto rischio di sviluppare la sm clinicamente definita. avonex deve essere interrotto nei pazienti che sviluppano una progressiva ms.